Tag: licensing
-
Digital Therapeutics Designed for Cancer/Covid-19 Stress
A digital health company is partnering with cancer advocacy organizations to provide electronic therapies to help patients deal with stresses from Covid-19.
-
AbbVie Acquires Coronavirus Antibody Therapy
Drug maker AbbVie is licensing a synthetic antibody to treat Covid-19 and SARS coronaviruses that the company began funding in June.
-
Biotech Licenses Precision Cancer Biologic to Genentech
A biotechnology company discovering synthetic proteins that target cancer-causing genetic mutations is licensing its lead product to biologics maker Genentech.
-
Trial Shows Stem Cell Therapy Slows M.S. Progression
Results of a clinical trial show a treatment for multiple sclerosis from patients’ stem cells slows progression of the disease and improves walking ability.
-
Bayer Gains Lung Cancer Therapy in $670M Deal
Global drug maker Bayer AG is licensing an engineered T-cell therapy to treat mesothelioma and other solid tumor cancers from biotech Atara Biotherapeutics.
-
Crispr Edits Out HIV-Like Genes from Monkey DNA
Researchers show the gene-editing technique Crispr can remove genes gained from infections similar to HIV in lab monkeys, as well as viral signals from their bodies.
-
Stem Cell Respiratory Therapy Licensed in $1.4B Deal
Global drug maker Novartis is acquiring a stem cell-based treatment for a serious respiratory disease associated with Covid-19 infections.
-
Start-Up Gains Drug Nanoparticle Manufacturing Tech
A new enterprise spun-off from University of Connecticut is acquiring a technology for continuous manufacturing of nanoscale drug particles.
-
Oral Drug Delivery Company Acquired in $1.8B Deal
Emisphere Technologies, developers of a process that makes biologic drugs available as oral medicines is being acquired by drug maker Novo Nordisk.
-
Covid-19 Drug Biotech Raises $300M in IPO
A company developing a treatment for Covid-19 infections taken as a tablet instead of infusion issued its initial public offering, or IPO, for common stock.